Ziad Hijazi1, Agneta Siegbahn2, Ulrika Andersson3, Bertil Lindahl4, Christopher B Granger5, John H Alexander5, Dan Atar6, Bernard J Gersh7, Michael Hanna8, Veli-Pekka Harjola9, John Horowitz10, Steen Husted11, Elaine M Hylek12, Renato D Lopes5, John J V McMurray13, Lars Wallentin4. 1. Uppsala Clinical Research Center, Department of Medical Sciences, Cardiology, and ziad.hijazi@ucr.uu.se. 2. Uppsala Clinical Research Center, Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden; 3. Uppsala Clinical Research Center. 4. Uppsala Clinical Research Center, Department of Medical Sciences, Cardiology, and. 5. Duke University, Medical Center, Durham, NC; 6. Department of Cardiology, Oslo University Hospital and Faculty of Medicine, Institute for Clinical Medicine, University of Oslo, Oslo, Norway; 7. Mayo Clinic College of Medicine, Rochester, MN; 8. Bristol-Myers Squibb, Princeton, NJ; 9. Division of Emergency Care, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; 10. University of Adelaide, Adelaide, Australia; 11. Medical Department, Hospital Unit West, Herning/Holstbro, Denmark; 12. Boston University Medical Center, Boston, MA; 13. BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, U.K.
Abstract
BACKGROUND: Although cardiac troponin is associated with outcomes in atrial fibrillation (AF), the complementary prognostic information provided by cardiac troponin I (cTnI) and cTnT is unknown. This study investigated the distribution, determinants, and prognostic value of cTnI and cTnT concentrations in patients with AF. METHODS: Samples were collected. At the time of randomization, we analyzed cTnI and cTnT concentrations of 14806 AF patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial using high-sensitivity assays. Correlations (Spearman), determinants (multivariable linear regression), and outcomes (adjusted Cox models and c-statistics) were investigated. RESULTS:Concentrations of cTnI and cTnT were correlated (r = 0.70) and measurable in most participants [cTnI 98.5% (median 5.4 ng/L, ≥99th percentile in 9.2%) and cTnT 93.5% (median 10.9 ng/L, ≥99th percentile in 34.4%)]. Renal impairment was the most important factor affecting the concentrations of both troponins. cTnI increase was more associated with heart failure, vascular disease, and persistent/permanent AF, and cTnT with age, male sex, and diabetes. Over a median 1.9 years of follow-up, patients with both troponins above the median had significantly higher risk for stroke/systemic embolism [hazard ratio (HR) 1.72 (95% CI 1.31-2.27)], cardiac death [3.14 (2.35-4.20)], and myocardial infarction [2.99 (1.78-5.03)] than those with both troponins below median (all P < 0.005). Intermediate risks were observed when only 1 troponin was above the median. When combined with clinical information, each marker provided similar prognostication and had comparable c-index. CONCLUSIONS:cTnI and cTnT concentrations are moderately correlated and measurable in plasma of most AF patients. The risk of stroke and cardiovascular events is highest when both troponins are above median concentrations. Each troponin provides comparable prognostic information when combined with clinical risk factors. ClinicalTrials.gov/NCT00412984.
RCT Entities:
BACKGROUND: Although cardiac troponin is associated with outcomes in atrial fibrillation (AF), the complementary prognostic information provided by cardiac troponin I (cTnI) and cTnT is unknown. This study investigated the distribution, determinants, and prognostic value of cTnI and cTnT concentrations in patients with AF. METHODS: Samples were collected. At the time of randomization, we analyzed cTnI and cTnT concentrations of 14806 AFpatients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial using high-sensitivity assays. Correlations (Spearman), determinants (multivariable linear regression), and outcomes (adjusted Cox models and c-statistics) were investigated. RESULTS: Concentrations of cTnI and cTnT were correlated (r = 0.70) and measurable in most participants [cTnI 98.5% (median 5.4 ng/L, ≥99th percentile in 9.2%) and cTnT 93.5% (median 10.9 ng/L, ≥99th percentile in 34.4%)]. Renal impairment was the most important factor affecting the concentrations of both troponins. cTnI increase was more associated with heart failure, vascular disease, and persistent/permanent AF, and cTnT with age, male sex, and diabetes. Over a median 1.9 years of follow-up, patients with both troponins above the median had significantly higher risk for stroke/systemic embolism [hazard ratio (HR) 1.72 (95% CI 1.31-2.27)], cardiac death [3.14 (2.35-4.20)], and myocardial infarction [2.99 (1.78-5.03)] than those with both troponins below median (all P < 0.005). Intermediate risks were observed when only 1 troponin was above the median. When combined with clinical information, each marker provided similar prognostication and had comparable c-index. CONCLUSIONS:cTnI and cTnT concentrations are moderately correlated and measurable in plasma of most AFpatients. The risk of stroke and cardiovascular events is highest when both troponins are above median concentrations. Each troponin provides comparable prognostic information when combined with clinical risk factors. ClinicalTrials.gov/NCT00412984.
Authors: Junichi Ishigami; Yuhree Kim; Yingying Sang; Steven P Menez; Morgan E Grams; Hicham Skali; Amil M Shah; Ron C Hoogeveen; Elizabeth Selvin; Scott D Solomon; Christie M Ballantyne; Josef Coresh; Kunihiro Matsushita Journal: Clin Chem Date: 2021-01-08 Impact factor: 8.327
Authors: Xiaoming Jia; Wensheng Sun; Ron C Hoogeveen; Vijay Nambi; Kunihiro Matsushita; Aaron R Folsom; Gerardo Heiss; David J Couper; Scott D Solomon; Eric Boerwinkle; Amil Shah; Elizabeth Selvin; James A de Lemos; Christie M Ballantyne Journal: Circulation Date: 2019-04-29 Impact factor: 29.690
Authors: Ziad Hijazi; Bertil Lindahl; Jonas Oldgren; Ulrika Andersson; Johan Lindbäck; Christopher B Granger; John H Alexander; Bernard J Gersh; Michael Hanna; Veli-Pekka Harjola; Elaine M Hylek; Renato D Lopes; Agneta Siegbahn; Lars Wallentin Journal: J Am Heart Assoc Date: 2017-06-23 Impact factor: 5.501
Authors: Dorien M Kimenai; Remy J H Martens; Jeroen P Kooman; Coen D A Stehouwer; Frans E S Tan; Nicolaas C Schaper; Pieter C Dagnelie; Miranda T Schram; Carla J H van der Kallen; Simone J S Sep; Jeroen D E van Suijlen; Abraham A Kroon; Otto Bekers; Marja P van Dieijen-Visser; Ronald M A Henry; Steven J R Meex Journal: Sci Rep Date: 2017-07-26 Impact factor: 4.379
Authors: Ziad Hijazi; Jonas Oldgren; Johan Lindbäck; John H Alexander; Stuart J Connolly; John W Eikelboom; Michael D Ezekowitz; Claes Held; Elaine M Hylek; Renato D Lopes; Salim Yusuf; Christopher B Granger; Agneta Siegbahn; Lars Wallentin Journal: Eur Heart J Date: 2018-02-07 Impact factor: 29.983